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Abstract 41 
Francisella noatunesis subsp. orientalis is a pathogen of tilapia and other warm water fish for 42 





vaccine was developed using the highly virulent isolate STIR-GUS-F2f7 and the oil-based 44 
adjuvant Montanide™ ISA 763A VG. The efficacy of the vaccine was assessed in red Nile 45 
tilapia via intraperitoneal (i.p.) injection using homologous experimental infection and 46 
correlates of protection such as seral antibody production and bacterial loads in the spleen. For 47 
immunisation, fish were i.p. injected with 0.1mL of the vaccine, the adjuvant alone or PBS.  At 48 
840 degree days post vaccination all fish were i.p. injected with 4.0x103 CFU/fish of pathogenic 49 
bacteria. The RPS at the end of the trial was 100% in the vaccinated group with significantly 50 
higher survival than in the adjuvant and control groups. The RPS in the adjuvant group was 51 
42%, and no significant difference was seen in survival between this and the PBS group. 52 
Moreover, significantly higher antibody titres in the serum and significantly lower bacterial 53 
loads in the spleen were detected in the vaccinated fish by ELISA and qPCR, respectively. 54 
These findings highlight the potential of autogenous vaccines for controlling francisellosis in 55 
tilapia. 56 
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1 Introduction 59 
Francisella noatunensis subsp. orientalis is a facultative intracellular pathogen responsible of 60 
francisellosis in several warm water fish species (Colquhoun & Duodu, 2011). In farmed Nile 61 
tilapia (Oreochromis niloticus L.), outbreaks caused by Francisella noatunensis subsp. 62 
orientalis usually occur in intensive culture systems with high stocking densities when water 63 
temperature drops below 25C (Ramirez-Paredes et al., 2017b; Soto et al., 2009; Soto et al., 64 
2012; Soto et al., 2018). Acute episodes of francisellosis in tilapia are commonly triggered by 65 
husbandry handling procedures and result in high levels of morbidity (80-90%) and mortality 66 
(50-90%) that can affect fish at all production stages (Birkbeck et al., 2011; Colquhoun and 67 
Duodu, 2011). 68 
Francisella noatunensis subsp. orientalis is one of the most pathogenic bacteria for tilapia 69 
(Klinger‐Bowen et al., 2016; Pulpipat et al., 2019; Ramirez-Paredes 2017b; Soto et al., 2009) 70 
and one of the main challenges that this industry currently faces globally. Nevertheless, despite 71 
the relevance of this pathogen, there are still no commercial vaccines available for its 72 
prevention and control.  73 
Soto et al. (2011) developed the first experimental vaccine for tilapia against Francisella 74 
noatunensis subsp. orientalis. This was a live attenuated strain, generated with an insertional 75 
mutation in the intracellular growth locus C gene (iglC) of strain recovered in Costa Rica which 76 
conferred a relative percentage survival (RPS) of 87.5% after experimental infection by 77 
immersion. However, due to the inherent risks of using live genetically modified 78 
microorganism (virulence reversion, dissemination into the environment and potential 79 
transmission to other species), most of the countries where tilapia is farmed do not grant 80 





be reasonably efficacious in that and further trails (Soto et al., 2014), it has not being licensed 82 
and is not commercially available in any country. 83 
In the present study, a whole cell inactivated autogenous vaccine against Francisella 84 
noatunensis subsp. orientalis was developed in 2014 for the first time. The vaccine was 85 
formulated using the commercial oil adjuvant Montanide™ ISA 763A VG and a highly virulent 86 
isolate (STIR-GUS-F2f7) recovered in 2012 from diseased red tilapia fingerlings in the United 87 
Kingdom (Ramirez-Paredes et al., 2017b). The efficacy of the vaccine was assessed by 88 
measuring survival rates after experimentally infecting vaccinated fish by intraperitoneal 89 
injection and its potency expressed in terms of RPS. Additionally, relevant correlates of 90 
protection including specific antibody (IgM) kinetics and quantification of bacterial loads in 91 
the spleen by qPCR were assessed.  92 
2 Materials and Methods 93 
2.1 Bacterial strain and experimental fish  94 
Francisella noatunensis subsp. orientalis (STIR-GUS-F2f7) was isolated in November 2012 95 
from a moribund red Nile tilapia, farmed in UK (Ramirez-Paredes et al., 2017b). The strain 96 
had been stored at -80 C in Modified Mueller-Hinton II cation-adjusted broth supplemented 97 
with 2% IsoVitaleX (MMHB) and 20% sterile glycerol. The strain was cultured in cystine heart 98 
agar with 2% bovine haemoglobin (CHAH) and MMHB following culture conditions indicated 99 
by Ramirez-Paredes et al. (2017b).  100 
Healthy naïve red Nile tilapia, 6-7 months/~11g (7-13 g), were obtained from the Tropical 101 
Aquarium (TA) at the Institute of Aquaculture, University of Stirling, Scotland UK. Fish in 102 





confirmed to be free of francisellosis by bacteriological and molecular methods prior to the 104 
study as outlined by Ramirez-Paredes et al. (2017b).  105 
2.2 Vaccine preparation and stability  106 
For vaccine preparation, an overnight culture (~18 h) was prepared in 15 mL of broth using 5x 107 
50 mL centrifuge tubes. The next day, the culture was centrifuged at 3500 x g for 20 min, the 108 
bacterial pellet washed 3 times with sterile 1x phosphate buffered saline (PBS) and adjusted, 109 
with PBS, to an OD600 of 1.0 (2.6 x 10
9 CFU/mL). 110 
For bacterial inactivation, the suspension was left mixing overnight at 4 °C in a sterile glass 111 
vessel, slow stirring at 100 rpm with 0.5% formalin (Formaldehyde 40% w/v) (Sigma-Aldrich, 112 
Dorset, UK). The formaldehyde was neutralised using 1/100 dilution of 15% sodium 113 
metabisulphite. This solution was then centrifuged, washed 3 times with PBS and readjusted 114 
to an OD600 of 1.0. Inactivation of the bacteria and sterility was confirmed by inoculating a 115 
subsample of the suspension onto CHAH and incubating at 28 oC for 7 days.  116 
For emulsification, the formalin killed bacterial suspension was mixed with a commercial oil 117 
adjuvant Montanide™ ISA 763A VG (SEPPIC, Puteaux Cedex, France), following the 118 
manufacturer’s guidelines for water-in-oil (W/O) emulsion in a 30/70 distribution of the 119 
continuous and dispersed phases (30% antigen to 70% adjuvant). Briefly, the emulsion was 120 
homogenised for 5 min with a hand blender as follows: 4000 rpm for the first 3 min, 4500 rpm 121 
for 30 s, 4000 rpm for 1 min and 4500 rpm for 30 s. The initial concentration of the inactivated 122 
bacteria (2.6 x 109 CFU/mL) was reduced with the emulsification to obtain a final concentration 123 
in the vaccine of 1.3 x 109 CFU/mL, to provide a dose of 1.3 x 108 CFU/fish when 0.1 mL of 124 





The final volumes to produce the vaccine were 100 mL of bacteria in PBS, 500 µL of 40% 126 
formalin and 1 mL of 15% sodium metabisulphite. The total volume of formalin-killed bacteria 127 
obtained was 60 mL of which 33 mL were added to 77 mL of adjuvant to obtain a final vaccine 128 
volume of 110 mL (Supplementary File 1).  129 
As indicated by the adjuvant manufacturer and Aucouturier et al. (2001), the vaccine emulsion 130 
was stored at 4 °C and its stability checked after 1, 15 and 60 days post preparation by 131 
performing a visual inspection of the emulsion. A droplet test was also performed to confirm 132 
that a water-in-oil emulsification had been successfully prepared by dropping 20 μL of the 133 
emulsion into a beaker containing bi-distilled water and confirming the droplet retained its 134 
shape. The conductivity of the emulsion was tested using an electrical conductivity meter 135 
(Cole-Parmer, England, UK) in a 50 mL tube at 4 C. The droplet size was observed under 136 
light microscope at 400X by placing a drop of vaccine on a slide glass with a cover slip without 137 
crushing the preparation. Finally, the syringeability in and out of fish was measured using a 1 138 
mL disposable insulin syringe with an integrated 30G x 8 mm needle and with stainless steel 139 
removable needles of different gauges i.e. 22G x 7 mm and 21G x 8 mm (Aqualife Services 140 
Ltd., Stirling, UK).  141 
2.3 Vaccine safety test  142 
To rule out possible side effects during the trial, thirty fish were intraperitoneally (i.p.) injected 143 
with twice the normal dose, i.e. 0.2 mL of the vaccine and kept at 28 °C in the TA for 30 days. 144 
Fish were anaesthetised with a dose of 100 mg/L of Tricaine Pharmaq 1000 mg/g (TPQ) 145 
(Pharmaq, Hampshire, UK) prior to the injection. After injection, the fish were checked twice 146 
a day during the first week examining them for acute side effects, such as changes in behaviour, 147 
lesions around the injection zone, sudden mortalities due to toxicity or other signs that could 148 





(30 days at 28 C) and necropsied to examine them for signs of chronic side effects such as 150 
internal lesions or adhesions. 151 
2.4 Vaccination 152 
A total of 468 red Nile tilapia were used in this experiment. The fish were equally distributed 153 
into 9 experimental tanks i.e. 3 treatment groups with 3 replicate tanks per group and 52 fish 154 
per tank. The treatments groups included (1) vaccinated fish, (2) fish injected with 1x sterile 155 
PBS and (3) fish injected with adjuvant only i.e. emulsified with 1x PBS (Table 1). The 156 
vaccinated and control groups were used to investigate the efficacy of the vaccine, while the 157 
adjuvant-only group was included to investigate possible immunostimulatory effects of the 158 
Montanide™ ISA 763A VG in the tilapia and if such stimuli could result in protection. 159 
All the fish were i.p. injected with 0.1 mL of their respective treatment i.e. vaccine, adjuvant 160 
or PBS using stainless hypodermic needles 22G x 7 mm and 21G x 8 mm (Aqualife Services 161 
Ltd., Stirling, UK). Prior to injection, fish were anaesthetised with a dose of 100 mg/L of TPQ. 162 
All fish were maintained in the TA at 28 °C for 30 days (~840 DD) for development of 163 
immunity. During this period, fish were fed twice at a daily rate of 2% biomass and sampled 164 
at four time points during the trial for serology. Twenty fish per replicate tank (60 per 165 
treatment) were used for the experimental challenge to evaluate vaccine efficacy. 166 
2.5 Experimental infections 167 
A pre-challenge was performed to confirm the dose that resulted in 60% mortality (LD60) in a 168 
group of naïve fish, housed in similar conditions to those in the vaccine study. This was carried 169 
out by injecting 20 fish with 2.4 x 104 CFU/fish in a 21 days trial. The dose was selected based 170 
on previous studies (Ramirez-Paredes 2015; Soto et al., 2009). For the main challenge 171 





of 4.0 x 103 CFU/fish live bacteria at 31 days post vaccination (d.p.v.) (Table 1 and 173 
Supplementary File 2). 174 
The pre-challenge and main challenge were performed following the methodology previously 175 
described (Ramirez-Paredes et al., 2017b). Briefly, fish were moved from the TA into a flow-176 
through system at the Aquatic Research Facility (ARF), where the water was maintained at 23 177 
± 2 oC to replicate the natural environmental conditions at which the disease occurs. 178 
Prior to performing the challenges, fish were acclimated for 10 days and fed twice daily at a 179 
rate of 2% biomass. For the infection process, fish were anaesthetised with a dose of 100 mg/L 180 
of TPQ and i.p. injected with the dose of bacteria as stated above. During the course of the 181 
infection the numbers of mortalities, as opposed to moribund and near-moribund fish, were 182 
kept to a minimum with continuous observations. The following criteria were considered as 183 
humane endpoints of infection, based on whether the fish were moribund or near moribund and 184 
the clinical signs they presented with one of the following severe signs: poor or no response to 185 
stimuli (slow or unable to swim off when touched with net), bilateral exophthalmia, total loss 186 
of equilibrium or total loss of buoyancy, or three of the following signs: unilateral 187 
exophthalmia, emaciation, hypo/hyperventilation, oedema, irregular swimming or tank 188 
placement, partial loss of balance, marked darkening of skin, lesions, haemorrhaging or natural 189 
concurrent infection.  190 
Diseased fish classed as moribund or near moribund (humane endpoint) were euthanised by 191 
Schedule 1 method (S1-M) i.e. with an overdose of TPQ followed by confirmation of death by 192 
brain destruction immediately after detection. All the euthanised fish were recorded throughout 193 
the experiments and accounted for posterior mortality and survival statistical analyses. 194 
To confirm specific mortalities, all moribund fish were necropsied, checked for gross 195 





Paredes et al., 2017b). The experiment was concluded when there was a period of at least five 197 
days with no mortalities. At the end of the trial all surviving fish were euthanized by S1-M and 198 
blood sampled to measure specific antibody levels in the serum by ELISA. Additionally the 199 
spleen of all survivors was collected and preserved in 95% ethanol for later bacterial 200 
quantification in the spleen by qPCR.  201 
2.6 ELISA development for specific IgM detection in tilapia serum  202 
An indirect enzyme linked immunosorbent assay (ELISA) was developed to measure the level 203 
of specific anti Francisella noatunensis subsp. orientalis IgM in the serum of fish. This was 204 
used to monitor the antibody kinetics throughout the immunisation period and at the end of the 205 
challenge in the survivors. For this, eight fish per replicate tank were euthanised by S1-M and 206 
bled from the caudal vein at 4, 9, 15 and 30 d.p.v.  Additionally, all surviving fish were 207 
euthanised and sampled at 40 days post challenge (d.p.c.) (Table 1).  Blood samples were stored 208 
overnight at 4 °C and centrifuged at 3000 ×g for 5 min for serum collection which was 209 
subsequently stored at -20 °C until analysis.  210 
The ELISA was performed according to Adams et al., (1995) with modifications. The 96-well 211 
ELISA plates (Immulone4 HBX-USA) were coated with 100 µL of 1% w/v poly-L-lysine in 212 
carbonate–bicarbonate buffer and incubated for 60 min at room temperature (~21 °C). Plates 213 
were then washed three times with a low salt wash buffer (LSWB) (0.02 mol/L Trizma base, 214 
0.38 mol/L NaCl, 0.05% (v/v) Tween 20, pH 7.2). Plates were coated with a bacterial 215 
suspension of isolate STIR-GUS-F2f7 re-suspended to an OD600 of 0.4 (~1.0 x 10
9 CFU/mL) 216 
with PBS. This was then added to each well (100 μL/well) and the plates were incubated 217 
overnight at 4 °C. The following day 50 μL of a 0.05% v/v solution of glutaraldehyde in LSWB 218 
was added to the plates and these were incubated at 21 °C for 20 min to fix the bacteria to the 219 





Non-specific binding was prevented by first adding 100 µL/well of 1/10 dilution of a 30% stock 221 
solution of hydrogen peroxide (Sigma-Aldrich, Dorset, UK) and incubating for 1h at room 222 
temperature. The plates were washed three times as before and further blocking was performed 223 
by incubating them after adding 250 µL/well of 5% w/v marvel (Premier Foods Group Ltd, 224 
England UK) in distilled water for 3 h at room temperature. Thereafter the plates were washed 225 
three times with 1x LSWB, and 100 µL/well of serum from 5 fish from the 3 different 226 
vaccinated groups (4, 9 and 30 dpv) and challenge survivors were added to the plates at a 1/500 227 
dilution in LSWB containing 1 % bovine serum albumin (BSA, Fisher scientific). Both positive 228 
(vaccinated and challenged fish serum) and negative (naïve fish serum) were used in each plate 229 
using the same dilution as tested sera. The plates were then incubated overnight at 4 C and 230 
after the incubation, plates were washed five times with high salt wash buffer (HSWB) (0.02 231 
mol/L Trizma base, 0.5 mol/L NaCl, 0.01% (v/v) Tween 20, pH 7.4) and left to soak for 5 min 232 
on the last wash. An anti-tilapia IgM monoclonal antibody (Aquatic Diagnostics Ltd, Stirling, 233 
UK) was added (100 μL/well) and the plates were incubated at room temperature for 60 min. 234 
The plates were again washed using 1x HSWB before adding 100 µL/well of goat anti-mouse 235 
immunoglobulin-G, conjugated with horseradish peroxidase (Sigma-Aldrich, Dorset, UK) 236 
diluted 1/3000 in  LSWB with 1% BSA. Plates were incubated for 60 min at room temperature 237 
and then washed again with HSWB as previously described. Substrate/chromogen (15 mL of 238 
substrate buffer [5.25 g citric acid, 2.05 g of sodium acetate, distilled water up to 15 mL, pH 239 
5.4] containing 5 µL of hydrogen peroxide (Fisher) and 150 µL of trimethyl-benzidine (TMB) 240 
di-hydrochloride (Sigma-Aldrich, Dorset, UK) was added to the plates, which were incubated 241 
for 5 min at room temperature. The reaction was terminated with the addition of 5 μL/well of 242 
2M H2SO4 and the absorbance measured at OD450 using a 96-well plate spectrophotometer 243 
(Biotek Instruments, Friedrichshall, Germany).  244 





The bacterial load in the spleen of surviving fish was determined at the end of the challenge 246 
experiment using a qPCR protocol previously described by Duodu et al. (2012). For this, 10 of 247 
the spleens previously preserved in 95% ethanol were randomly selected from each treatment 248 
for genomic DNA extraction. The DNA was extracted from 20 mg of the fixed spleen samples 249 
using the DNeasy blood and tissue kit (Qiagen, UK). The concentration of the extracted DNA 250 
was measured using a nanodrop ND-1000 Spectrophotometer (Thermo Scientific, UK) and 251 
standardised to 100 ng/µL with Milli-Q water (Thermo Scientific, UK). One µL of each DNA 252 
sample was visualised in a UV illuminator (Bio Imaging, Syngene) after electrophoresis on a 253 
1% (w/v) agarose gel (Sigma-Aldrich, Dorset, UK) containing 0.1 µg/mL ethidium bromide 254 
(Sigma-Aldrich, Dorset, UK) in Tris-EDTA (TAE) buffer. The assay was performed in a 255 
LightCycler® 2.0 (ROCHE) using a 20 L reaction volume consisting of 0.3 M from each 256 
primer (Eurofins Genomics, UK), 1x Luminaris color HiGreen™ qPCR master mix 257 
(ThermoScientific), 1 L DNA template and nuclease free water (ThermoScientific) up to 20 258 
L. The PCR cycling conditions were 50 C for 2 min for uracil-DNA glycosylase enzyme 259 
activity, 95 C for 10 min to start denaturing the UNG enzyme and activate the DNA 260 
polymerase enzyme then 45 cycles at 95 C for 15 s and 60 C for 1 min. Melting curve analysis 261 
was performed with 1 cycle at 95 C for 30 s, 55 C for 30 s and 95 C for 30 s. All samples 262 
were run in triplicate. After the run, analysis was performed using the default calculation of the 263 
quantification cycles (Cq values). 264 
2.8 Statistical analysis 265 
The vaccine efficacy was estimated by calculating the relative percent survival (RPS). This 266 
value indicates the proportional relationship between mortality in the vaccinated group and the 267 





𝑅𝑃𝑆 =  [1 − (
% 𝑚𝑜𝑟𝑡𝑎𝑙𝑖𝑡𝑦 𝑖𝑛 𝑣𝑎𝑐𝑐𝑖𝑛𝑎𝑡𝑒𝑑 𝑓𝑖𝑠ℎ
% 𝑚𝑜𝑟𝑡𝑎𝑙𝑖𝑡𝑦 𝑖𝑛 𝑛𝑜𝑛𝑣𝑎𝑐𝑐𝑖𝑛𝑎𝑡𝑒𝑑 𝑓𝑖𝑠ℎ
)] × 100% 269 
The RPS of the adjuvant-only group was also calculated as a comparison. Differences in 270 
survival were determined using the product limit method of Kaplan and Meier and the Log-271 
rank (Mantel–Cox) test was used to compare survival curves. The specific antibody levels in 272 
the 3 different treatments, at the different time points were analysed by one-way ANOVA 273 
followed by Welch's test. The bacterial loads quantified by qPCR were also analysed with a 274 
one way ANOVA, paired comparisons between vaccinated and unvaccinated fish were 275 
analysed using a Tukey's test. In all cases, a p-value of < 0.05 was considered significant. All 276 
statistical analyses were carried out using the GraphPad Prism 8.02 software package 277 
(GraphPad Software Inc., San Diego, CA, USA).  278 
2.9 Ethics 279 
The vaccination, infection and associated procedures were performed in accordance with the 280 
UK Animal (Scientific Procedures) Act 1986 and the University of Stirling Animal Welfare 281 
and Ethical Review Body (AWERB) regulations. All the protocols were approved by the 282 
University of Stirling AWERB. 283 
3 Results 284 
3.1 Vaccine stability 285 
An appropriate water-in-oil emulsion was observed in the drop test, with a conductivity of 286 
30 μs/cm. The microscopic particles observed were 1 μm in size and were homogenously 287 
distributed in the continuous and dispersed phase of the mixture, showing a dense liquid 288 
compatible with the 70/30 emulsion. No separation of the liquid phases was observed when 289 
examined 24 h after emulsification, indicating that the vaccine was suitably stable for injection 290 





confirmed that the emulsion remained stable during this time. During the syringeability test, 292 
the needles in the insulin syringes were not successful administering the vaccine as due to the 293 
viscosity of the final product the process was slow, complicated and some of the syringes broke 294 
while injecting the fish. For this reason hypodermic needles 22G x 7 mm and 21G x 8mm were 295 
used to vaccinate the fish (Supplementary File 3).  296 
3.2 Vaccine safety  297 
The 30 fish injected with the double dose of vaccine remained healthy, with no acute side 298 
effects evident, such as changes in behaviour i.e. lethargy, lack of feeding, aggression, gaping, 299 
flashing etc. No adhesions between mesentery and the internal wall of the peritoneal cavity or 300 
between sections of the intestines or the intestines and other organs were seen and therefore 301 
the fish were classified as “0” according to the Speilberg scoring system (Midtlyng et al., 1996). 302 
All fish had a droplet of the vaccine in the peritoneal cavity, always located dorsal, caudal and 303 
lateral to the right (below the swim-bladder, posterior section of the peritoneal cavity). Smaller 304 
vaccines droplets could also be observed distributed randomly within the peritoneal cavity in 305 
about 30% of the fish. The droplets were contained in a smooth soft transparent sac with 306 
vascularisation. Although 12 fish (40%) had dark pigments within the peritoneal cavity and 307 
mesenteric fat, these were not linked to the vaccine as peritoneal pigmentation is a common 308 
feature of tilapia. As expected, during the immunisation period (~840 DD) all fish vaccinated 309 
with the normal dose remained healthy and no mortalities or signs of acute toxicity or chronic 310 
side effects were seen.  311 
3.3 Bacterial infection  312 
Administration of 2.4 x 104 CFU/fish produced a cumulative mortality of 90% by 21 d.p.c. in 313 





fish with a log10 lower dose to test the efficacy of the vaccine, with the actual dose used 315 
determined to be 4.0 x 103 CFU/fish based on colony counts. 316 
When moribund fish were dissected, granulomas were observed in their spleens and kidneys, 317 
with varying degrees of severity (Figure 1). Some spleens were larger than normal, with dark 318 
red coloration and white nodules in 80-90% of the parenchyma, others were bright red with 90-319 
100% granulomas and some others showed splenomegaly with large nodules and a white 320 
membranous lining of the capsule of the spleen, which extended over the majority of the 321 
peritoneal cavity. Head kidneys appeared enlarged, haemorrhagic and full of granulomas, and 322 
in some cases the organ protruding ventrally towards the anterior section of the peritoneal 323 
cavity, in contact with the spleen, liver, and gut sections. Other organs such as the gonads, gut 324 
and posterior kidney were also affected. Bacterial recovery was achieved from 100% of the 325 
moribund fish sampled. 326 
Histopathological sections of the affected organs showed typical granuloma lesions. The 327 
bacteria were seen frequently contained within enlarged macrophages or found covered with 328 
fibrin and enclosed by accumulation of phagocytic cells, that outlined by inflammatory cells 329 
and fibroblasts. Concomitant mononuclear infiltration and increased vascularisation were also 330 
noted around the in the affected areas (Figure 2). 331 
3.4 Vaccine efficacy  332 
A significant level of protection against the bacterial challenge was obtained for the vaccinated 333 
group compared to the control and adjuvant groups (p<0.0001). (Figure 3). However, no 334 
significant difference was seen between adjuvant and control treatment (Table 2). The 335 
mortalities in the control group started by 8 d.p.c. and reached an average of 63.3 ± 2.9% by 336 
34 d.p.c. The mortalities in the adjuvant group started at 13 d.p.c. and reached an average of 337 





experiment by 40 d.p.c. The RPS value at the end of the experiment was 100% for the 339 
vaccinated group and 42% for the adjuvant group. The mortality data is presented in 340 
Supplementary File 4. 341 
3.5 Kinetics of specific IgM response of vaccinated fish 342 
The results of the ELISA confirmed that there was no significant difference in the levels of 343 
specific anti Francisella noatunensis subsp. orientalis IgM between vaccinated, adjuvant and 344 
control groups in the first 15 d.p.v. However, the vaccinated fish started to produce 345 
significantly higher levels of specific IgM by 30 d.p.v. (p<0.001) compared to the other two 346 
groups (Figure 4). No specific antibody response was seen in serum sampled from the adjuvant 347 
or control groups prior to challenge. All the survivors showed increased antibody production 348 
after the infection with the vaccinated fish displaying the highest titres (Figure 4). 349 
3.6 Quantitative PCR (qPCR) for estimation of bacteria load in the spleens of infected 350 
fish 351 
Molecular quantification of bacterial loads in the spleen of survivors revealed significantly 352 
lower Francisella noatunensis subsp. orientalis loads i.e. pathogen genome copies, in the 353 
vaccinated than in the adjuvant-only (p<0.05) and PBS-injected (p<0.001) fish. The fish 354 
immunised only with the adjuvant displayed significantly lower loads than the control fish 355 
(p<0.05) (Figure 5). 356 
4 Discussion 357 
Francisellosis remains one of the most important infectious diseases in aquaculture for which 358 
no licenced vaccines are available. Autogenous vaccines are custom made formulations that 359 
have the potential to be rapidly developed and deployed when no off-the-shelf fully licensed 360 





pathogens isolated directly from the sites where they will be delivered i.e. have the capacity to 362 
confer immunity against homologous challenges (Haskell et al, 2004).  363 
Under these circumstances, the formulation of autogenous vaccines is a logical scenario but as 364 
yet, remains as an unexplored option to control francisellosis in tilapia. The present study was 365 
therefore carried out using a whole cell inactivated vaccine against Francisella noatunensis 366 
subsp. orientalis, which had an excellent efficacy in red Nile tilapia using a homologous isolate 367 
to assess its efficacy.  368 
The vaccine here developed was found to be safe with adequate bacterial inactivation achieved, 369 
residual formaldehyde neutralisation and absence of acute or chronic side effects to the fish 370 
during the safety test. Although the safety test was run for 30 days, the first 7 days are 371 
considered the most critical for this assessment. 372 
The vaccine was also considered stable as the use of a high speed mixer resulted in an efficient 373 
water-in-oil 70/30 (70% adjuvant / 30% antigen) emulsion that was easy to administer using 374 
stainless steel 21-22 gauge needles. In the emulsion, the antigenic component was the primary 375 
inducer of the specific adaptive immune response while the adjuvant enhanced and extended 376 
such response.  377 
According to Tafalla et al. (2014) such role of the adjuvants is achieved in part by acting as a 378 
delivery vehicles for the antigens and also by stimulating immune system through inherent 379 
immunostimulatory properties. Although the exact mechanisms of how adjuvants work are 380 
mostly unknown, according to Cox & Coulter (1997) five modes of action have been 381 
recognised: (1) Immunomodulation: the ability to modify the cytokine network. (2) 382 
Presentation: the ability to preserve the conformational integrity of an antigen and to present 383 
the antigen to appropriate immune effector cells. (3) Cytotoxic T-lymphocyte (CTL) induction: 384 





immune effector cells, generally via antigen presentation cells. (5) Depot generation: 386 
generation of a short-term or long-term depot to give a continuous or pulsed release. 387 
In the present study, fish in the adjuvant-only group had a better survival rate (RPS 42%) than 388 
the control fish, making clearly evident that the commercial adjuvant Montanide™ ISA 763 A 389 
VG acted as an immunostimulant for Nile tilapia. It is thought that this could have been caused 390 
by immunomodulation, CTL induction and/or depot generation mode of actions as no specific 391 
antibody production was seen in this group at any point after vaccination (Cox & Coulter, 1997; 392 
Tafalla et al., 2014). The immunostimulation properties of the adjuvant allowed the fish to 393 
control bacterial replication to some degree and this was reflected in the qPCR results of the 394 
only adjuvant group where significantly lower bacterial loads than in the control fish were seen.  395 
If the immunostimulation properties were seen in the only adjuvant group it can be assumed 396 
that these properties were also present in the vaccine group. However further research 397 
comparing the expression of cell mediated immune genes in adjuvant, vaccinated and control 398 
groups is needed to clarify if these mechanisms of immunity are stimulated by the adjuvant 399 
ISA 763A VG and to better understand the interactions between this adjuvant and the tilapia 400 
immune system.  401 
As discussed by Munang’andu & Evensen (2015) the type of adaptive immune response is 402 
highly influenced by the site of antigen uptake i.e. antigens deposited extracellularly primarily 403 
evoke humoral immune responses, while antigens deposited intracellularly evoke both humoral 404 
and cellular mediated immune responses. It is believed that in this study the external aqueous 405 
phase of the water-in-oil emulsion secured a correct preservation and incorporation of the killed 406 
antigen (antigen delivery role) into the intracellular space of the immune effector cells (local 407 





continuous release of specific IgM (Aucouturier et al., 2001; Cox & Coulter, 1997; Tafalla et 409 
al. 2014). 410 
It is possible that such a strong humoral immune response controlled the extracellular stage of 411 
the bacterial infection especially during the early stages of the infection presumably preventing 412 
entry and replication of live pathogenic bacteria into the immune cells of the fish (Soto et al., 413 
2010). Most importantly although some individual variation was seen amongst the vaccinated 414 
fish, the average humoral response reached a signature of protective immunity as defined by 415 
Pulendran et al. (2010) by day 25 p.v. that fell well within the concept of herd immunity 416 
(Anderson and May, 1985; Gudding, 2014). Further research is needed to understand the exact 417 
mechanisms that induced the potent and rapid humoral response seen in the vaccinated fish and 418 
if the vaccine is also able to stimulate cellular immune response. 419 
Previous reports of Francisella infections in humans have reported development of immunity 420 
in naturally infected individuals (Koskela & Salminen, 1986). Interestingly the antibody titres 421 
in the survivors of the control group was above the threshold of protection confirming that this 422 
group of fish had already developed humoral immunity to Francisella noatunensis subsp. 423 
orientalis  infection.  It is possible that this immunity had potentiated the immunity conferred 424 
by the vaccine and adjuvant. These observations correlated with the bacterial loads seen in 425 
spleen determined from the qPCR in all the treatments. Whether the survivors from these 426 
groups would have eventually eliminated the infection or became carriers or vertical/horizontal 427 
transmitters stills remains unknown.  428 
The correlation between the RPS values, differences in the survival rate, antibody titres and 429 
bacterial loads observed in this study confirmed that the vaccine developed here was 100% 430 
effective in protecting red Nile tilapia from the bacterial challenge administered by i.p. 431 





at a commercial level to develop autogenous vaccines as a solution to control francisellosis in 433 
farms or areas where the problem is endemic.  434 
Further research is needed to investigate the efficacy of this vaccine in scenarios such as higher 435 
challenge doses and other infection routes i.e. immersion and cohabitation. Moreover, this 436 
approach could also be used to explore the possibility of cross protection between isolates from 437 
different origins, as previous studies have revealed high genetic homogeneity at genome level 438 
between isolates obtained from different countries, fish species, and over time (Gonçalves et 439 
al., 2016; Ramirez-Paredes 2015; Ramirez-Paredes et al., 2017a; Sjödin et al., 2012).  440 
5 Conclusion 441 
The whole cell inactivated vaccine developed in this study provided excellent results, 442 
protecting red Nile tilapia against experimentally induced francisellosis (RPS = 100%) using 443 
homologous isolate. The protection correlated with systemic IgM responses and bacterial loads 444 
as confirmed by ELISA and qPCR, respectively.  445 
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Table 1. Experimental design of vaccination trial and sampling point for correlates of protection. 
Feature Vaccine Adjuvant  Control 
Immunisation (No. fish/ replicate) 52 x 3 52 x 3 52 x 3 
Inoculum (100 μl via i.p. injection) 1.3x109 CFU/ml  + Adjuvant 70% Adjuvant + 30% PBS PBS 
Sampling points for serology (d.p.v.) 4, 9, 15 and 30 4, 9, 15 and 30 4, 9, 15 and 30 
No. fish/ No. replicates 20 x 3 20 x 3 20 x 3 
Challenge dose  103 CFU/fish  103 CFU/fish  103 CFU/fish  
Sampling for pathology, serology and qPCR 40 d.p.c. 40 d.p.c. 40 d.p.c. 
d.p.c. = days post challenge. 
 
 
       
Table 2. Survival analysis of different treatment groups showing results between treatments and the overall comparisons results. 
Comparisons between treatments Overall Comparisons 













(and Cox) test 
df significance 
vaccinated   control 38.6 5 <0.0001 yes 41.39 8 <0.0001 
vaccinated   adjuvant 30.12 5 <0.0001 yes       






Figure 1. Gross pathology of experimentally infected naïve red Nile tilapia showing varying degrees of affection. A. 539 
Necropsy of moribund fish displaying erratic swimming and ascites, the black arrows point at enlarged and haemorrhagic organs 540 
including gills, wall of the peritoneal cavity and liver. The white arrows point at formation of white nodules in head kidney and 541 
mesentery. B. Spleen from fish shown in A, the organ presents severe affection with white nodules covering 100% of the 542 
parenchyma. C. Head kidney with moderate white nodule formation. D. Spleen from fish shown in C, the organs displays 543 
moderate affection with white nodules in the parenchyma. 544 
Figure 2. Histological sections of the kidney of tilapia experimentally infected with francisellosis stained with H&E. A. 545 
The arrows indicate fully formed granulomas. Scale bar = 100 µm. B. Higher magnification 100x of one the granulomas with 546 
necrotic centre, encased by macrophages, mononuclear leukocytes and fibroblasts. 547 
Figure 3. Cumulative percentage survival of red Nile tilapia during the main experimental challenge. The three replicate 548 
tanks of the three treatment groups (vaccinated, adjuvant alone and control) were experimentally infected with the homologous 549 
strain STIR-GUS-F2f7 at 840 degree days post vaccination. Survival for each replicate tank is shown. Relative percent survival 550 





Figure 4. Serum antibody levels of vaccinated, adjuvant-injected and PBS control tilapia post vaccination and post 552 
challenge. Each bar represents average OD450 values of 5 fish per treatment ± SD. Horizontal dashed line represents cut-off 553 
calculated from average of the background multiplied by 3. Vertical dashed line divides vaccinated fish at days 4, 9, 15 and 30 554 
post vaccination from challenge survivors at day 40 post challenge. Asterisks indicates significant difference, ns= not significant 555 
different (p0.05), * (p0.05), *** (p0.0001) d.p.v. = days post vaccination, d.p.c. = days post challenge. 556 
Figure 5. Francisella noatunensis subsp. orientalis loads on the spleen of vaccinated, adjuvant-injected and control group 557 
survivors at day 40 post challenge. Each bar represents average copy number of 10 spleen samples per treatment ± SD. 558 
Asterisks indicate significance difference * (p0.05), *** (p0.0001). 559 





